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ABSTRACT 
DIABETES MELLITUS IS ASSOCIATED WITH INCREASED PREVALENCE OF LATENT 
TUBERCULOSIS INFECTION: FINDINGS FROM THE NATIONAL HEALTH AND 
NUTRITION EXAMINATION SURVEY, 2011-2012 
By 
 
MARISSA MARGARET BARRON 
 
APRIL 14, 2017 
 
Background: Type 2 diabetes mellitus is associated with threefold higher risks of active 
tuberculosis (TB) and an estimated 15% of the 10.4 million annual incident TB cases are 
attributable to diabetes. While the relationship between diabetes and TB disease is well-
established, little is known about the association between diabetes and latent TB infection 
(LTBI).   
Methods: We performed a cross-sectional analysis of data from the 2011-2012 cycle of the 
National Health and Nutrition Examination Survey. Participants aged 20 years were eligible for 
this analysis. Diabetes status was defined by glycated hemoglobin (HbA1c) as no diabetes 
(5.6%), prediabetes (5.7-6.4%), and diabetes (6.5%); participants were defined as having 
diabetes if they self-reported a diagnosis, regardless of HbA1c. LTBI was defined by interferon 
gamma release assay (IGRA) as positive, negative, or indeterminate. We used logistic regression 
to estimate the adjusted odds ratio and 95% confidence interval of LTBI comparing participants 
with diabetes and prediabetes to those with no diabetes.  
Results: Overall the prevalence of diabetes was 11.4% (95%CI 9.8-13.0%) and 22.1% (95%CI 
20.5-23.8%) had prediabetes. The prevalence of LTBI was 5.9% (95%CI 4.9-7.0%). After 
adjusting for cofounding factors, the odds of prevalent LTBI was greater among adults with 
diabetes (aOR 1.91, 95%CI 1.16-3.16) compared to those without diabetes.  
Conclusion: Diabetes is associated with LTBI among adults in the US, even after adjusting for 
confounding factors. Given diabetes increases the risk of active TB, patients with co-prevalent 
diabetes and LTBI may be targeted for LTBI treatment. 
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CHAPTER I 
INTRODUCTION 
1.1 Background 
Tuberculosis (TB) is an infectious disease that is spread by the causative agent 
Mycobacterium tuberculosis (MTB). TB generally affects the lungs (known as 
pulmonary TB), but may also spread to other areas of the human host (known as 
extrapulmonary TB)[1]. The majority of individuals who become infected with MTB do 
not develop infectious, symptomatic TB (also known as active TB); instead, their 
immune systems are able to contain the MTB infection, which leads to the development 
of latent tuberculosis (LTBI)[2, 3] Individuals with LTBI are not symptomatic or 
infectious so long as their immune system contains the MTB infection. 
In 2015, an estimated 10.4 million new cases of TB occurred worldwide, and 
there were 1.4 million deaths attributed to TB[1]. In addition, an estimated one-third of 
the world population has LTBI[2, 4]. In the general population, the proportion of persons 
with LTBI that develop TB is low, but the risk of reactivation of LTBI to TB is increased 
by comorbidities that affect immune responses[2, 5]. Reactivation of LTBI to TB only 
occurs in about 10% of all infected individuals[2], but the risk of progression to TB 
among patients with diabetes mellitus (DM) is approximately 3 times the risk of the 
general population[6-10]. Although individuals with LTBI are not infectious, they are a 
reservoir for TB in their communities. According to a review article by Getahun et al., 
modeling has shown that if a mere 8% of individuals with LTBI were “permanently 
protected” annually, the incidence of TB worldwide in 2050 would be 14 times as low as 
in 2013 
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The association between TB and DM has been known about for centuries[11]. 
Studies involving TB patients have shown that previously diagnosed DM is one of the 
most commonly occurring co-morbidities[6]. Of concern, the global prevalence of DM is 
increasing rapidly, and the largest increases in DM prevalence will occur in settings 
where TB burdens are greatest[11-13]. An estimated 95% of TB cases occur in low- and 
middle-income countries, and approximately 70% of individuals with DM reside in these 
same countries[12]. In 2014, an estimated 415 million adults had type 2 DM and by 2040 
the prevalence is expected to reach 642 million adults worldwide[14]. Given the rapid 
rise in global DM prevalence and the increased risk of TB in this population, an estimated 
15% of all TB cases are currently attributed to DM[7, 15]. 
Observational studies have shown that DM increases the risk of TB. A 2012 
cohort study conducted by Baker et al. found that individuals with type 2 DM (whether 
treated or not) had a significantly higher risk of TB than individuals without type 2 DM 
(adjusted hazard ratio, 2.09 [95% confidence interval, 1.10-3.95])[4]. Baker et al. also 
found the risk of TB to be correlated with the amount of type 2 DM-associated 
complications, with individuals with ≥2 type 2 DM complications having more than 3 
times the risk of TB than individuals without type 2 DM (odds ratio, 3.45 [95% 
confidence interval, 1.59-7.50])[4]. A meta-analysis conducted by Jeon et al. of 13 
observational studies found a pooled risk ratio of 3.1 (95% confidence interval, 2.3-4.3) 
for active TB comparing individuals with type 2 DM to individuals without type 2 
DM[16]. 
Our study involved the use of data from the 2011-2012 cycle of the National 
Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of DM 
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and LTBI among the civilian, non-institutionalized United States population. NHANES 
has been conducted in the United States since the early 1960s and focuses on various 
health issues and populations each cycle. Each year, NHANES retrieves data on 
approximately 5,000 individuals meant to be a nationally representative sample. 
Questionnaires, physical examinations, and laboratory measurements are used together to 
obtain information on risk factors for various diseases and the prevalence of certain 
diseases in the United States[17]. 
1.2 Gap and Purpose of Study 
Results from recent studies using data from NHANES suggest an association 
between LTBI and DM[18]. A 2016 cross-sectional study conducted by Hensel et al. also 
found an association between LTBI and DM, with 43.4% and 39.1% of QFT-positive 
(QuantiFERON-TB test) individuals having DM and pre-DM, respectively, compared to 
25.9% of QFT-positive individuals not having DM or pre-DM[19]. Although studies 
have shown an association between LTBI and DM, the association has not been further 
investigated using NHANES data. Using data from the 2011-2012 cycle of NHANES, we 
hypothesized that DM and pre-DM are associated with LTBI.      
 The objectives of this study are to: 
 1. Investigate participant characteristics associated with DM and LTBI 
 2. Determine the association of DM and pre-DM with LTBI 
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CHAPTER II 
REVIEW OF THE LITERATURE 
2.1 Latent Tuberculosis Infection 
Approximately one-third of the global population is estimated to have latent 
tuberculosis infection (LTBI)[2, 3]. There were an estimated 10.4 million new cases of 
TB globally and 1.4 million deaths attributed to TB in 2015[1]. Though the majority of 
individuals infected with Mycobacterium tuberculosis (MTB) never progress to 
symptomatic, infectious active tuberculosis (TB), these individuals with LTBI serve as a 
reservoir for TB in their communities[3].  
For individuals who become infected with MTB, progression to active TB only 
occurs in approximately 5-10% of those infected[9]. MTB will be contained by the 
immune system for the majority of those infected, and these individuals will develop 
asymptomatic, non-infectious LTBI[2, 3]. The immune response to MTB begins when 
the bacteria come into contact with alveolar macrophages of the lungs. In response, these 
macrophages upregulate production of pro-inflammatory cytokines to signal the presence 
of an infection[2]. As a result, cells such as T lymphocytes, B cells, fibroblasts, and 
dendritic cells are recruited to the site of infection, which in the case of LTBI leads to the 
formation of a granuloma containing the bacteria. Bacteria that survive granuloma 
formation become a reservoir of latent infection[2].  
Studies have shown that the levels of certain cellular immune signals may 
function in the maintenance of the dormancy of LTBI. Pro-inflammatory cytokines TNF-
α and IFN-γ are known to be vital in maintaining the dormancy of LTBI by keeping MTB 
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contained in granulomas[2, 20, 21]. In a 2015 cross-sectional study in India involving 39 
recently diagnosed active TB patients and 35 household contacts with LTBI as confirmed 
by positive QuantiFERON®-TB Gold In-Tube Test (QFT-GIT) and negative chest X-ray 
and smear microscopy, Pathakumari et al. reported that, following stimulation with two 
MTB antigens, Rv2204c and Rv0753c, higher levels of IFN-γ were seen in whole blood 
samples of those with LTBI compared to those with active TB[22]. Other studies have 
also reported increased levels of TNF-α and IFN-γ in patients with LTBI compared to 
patients with active TB[21, 23, 24]. Elevated levels of antimicrobial peptides (AMPs), 
such as human β-defensin-2 (HBD-2), have been observed in patients infected with 
LTBI[25-27]. β-defensins may play an important role in maintaining the dormancy of 
LTBI, as they are able to inactivate one of the crucial proteins involved in the 
proliferation of bacteria, ftsZ factor[25]. 
In a cross-sectional analysis of data from the 2011-2012 cycle of the National 
Health and Nutrition Examination Survey (NHANES), Mancuso et al. determined the 
prevalence of LTBI among the civilian, non-institutionalized population to be 
approximately 4.4% by positive tuberculin skin test (TST) results and approximately 
4.8% by positive QFT-GIT[28]. Mancuso et al. reported that QFT-GIT test results had a 
higher specificity, especially among individuals who had received the Bacillus Calmette-
Guérin (BCG) vaccine[28]. QFT-GIT may be a more reliable test for LTBI, as false 
positives using the TST may occur due to cross-reactive antigens in the purified protein 
derivative (PPD) also being present in non-pathogenic mycobacteria[29]. 
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2.2 Diabetes Mellitus 
Approximately 415 million adults were living with type 2 diabetes mellitus in 
2014, and the prevalence of type 2 diabetes is projected to increase to 642 million adults 
worldwide by 2040[14]. Although type 1 diabetes is also a major issue, type 2 diabetes 
currently comprises approximately 90% of the cases of diabetes worldwide[8]. Among 
the many known risk factors for developing diabetes, obesity is known to predispose an 
individual to diabetes[30-32]. The main mechanism by which obesity predisposes an 
individual to developing diabetes is the elevated levels of pro-inflammatory cytokines, 
such as TNF-α, seen in adipose tissue of obese individuals[30-32]. The elevated levels of 
pro-inflammatory cytokines such as IL-1β, C-reactive protein (CRP), IL-6, IL-8, and 
MCP-1 have been shown to precede the development of diabetes[30, 31, 33]. Elevated 
levels of pro-inflammatory cytokines such as TNF-α increase the risk of developing 
insulin resistance and beta cell dysfunction, key features of diabetes[30, 33].  
Diabetes is associated with a chronic, low-grade inflammation that is marked by 
increased levels of pro-inflammatory cytokines that reflect activation of innate 
immunity[33]. In a 2015 study involving 14,876 men and women from the Gutenberg 
Health Study cohort, researchers found elevated plasma levels of CRP in patients with 
diabetes and pre-diabetes compared to patients without diabetes[31]. CRP is known to be 
a marker of inflammation that increases in response to increased inflammation and may 
be associated with insulin resistance syndrome[34]. Other studies have also demonstrated 
diabetes to be associated with elevated levels of several key pro-inflammatory cytokines, 
such as CRP, IFN-γ, TNF-α, IL-1β, IL-6, and IL-17[31, 34-44].  
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2.3 Co-Occurring Diabetes and Tuberculosis 
Despite reactivation of LTBI to active TB only occurring in approximately 10% 
of individuals infected with MTB[2], certain comorbidities, such as human 
immunodeficiency virus (HIV)[3, 5, 9] and diabetes[3, 6, 8], have been shown to 
significantly increase the risk of LTBI reactivation to active TB. The risk of reactivation 
to active TB for patients with co-occurring HIV and LTBI may exceed 10% per year, 
while the average risk of reactivation to active TB for those with LTBI only is between 
10% and 20% for their entire lifetime[5]. In a review article by Restrepo et al., the risk of 
developing active TB in those with co-occurring LTBI and HIV is estimated to be more 
than 50 times the risk in those without co-occurring HIV[9]. Among adults with HIV in 
under-developed countries, the most common cause of death is TB[5]. In addition to HIV 
and diabetes, there are many other factors that may impact an individual’s risk of 
reactivation LTBI to active TB, including being homeless, being from a country with a 
high burden of TB, and being of very young or very old age[3]. 
Risk of reactivation of LTBI to active TB among individuals with co-occurring 
diabetes has been found to be approximately three-times the risk of reactivation among 
individuals without diabetes[6-8]. With diabetes causing such a significant impact on the 
risk of reactivation to active TB, an estimated 15% of all TB cases are currently 
attributable to diabetes[7, 15]. The proportion of TB cases attributable to diabetes may 
increase in the future[45], as the prevalence of diabetes is projected to increase to 552 
million individuals worldwide by 2030, and the majority of this increase will likely occur 
in low- and middle-income countries with high TB burdens[11, 12]. Currently, 
approximately 95% of patients with TB live in developing, low- and middle-income 
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countries, such as in Southeast Asia, and approximately 70% of patients with diabetes 
reside in those same countries[12]. 
Co-occurring diabetes and LTBI has been shown to have an impact on both the 
innate and adaptive immune system. It is due to these immunologic effects that having 
diabetes increases the risk of developing active TB[6, 19]. While not as much is known 
regarding immunologic dysfunction during co-occurring diabetes and LTBI, there are a 
few notable studies that have analyzed biomarkers present in individuals with both 
illnesses. In a 2014 case-control study of 90 patients with LTBI (30 with co-occurring 
diabetes, 30 with co-occurring pre-diabetes, 30 without diabetes), as determined by 
positive QFT-GIT and normal chest radiograph, and 60 uninfected controls (30 with co-
occurring diabetes and 30 without diabetes), Kumar et al. measured the circulating levels 
of several cytokines. The study found decreased circulating levels of the pro-
inflammatory cytokines IFN-γ, TNF-α, IL-1β, IL-2, IL-17, and IL-18 in subjects with co-
occurring LTBI and diabetes compared to subjects with LTBI only[46]. Pro-
inflammatory cytokines are known to be vital in the immune response against 
mycobacterial infections, so decreased levels of these pro-inflammatory cytokines in 
individuals with co-occurring diabetes and LTBI may increase the risk of reactivation to 
active TB[46]. 
AMPs may also be related to immune dysfunction seen in co-occurring diabetes 
and LTBI. In a 2011 cross-sectional study of 30 subjects with diabetes (10 uninfected, 10 
with co-occurring LTBI, 10 with co-occurring active TB) and 30 subjects without 
diabetes (10 uninfected, 10 with co-occurring LTBI, 10 with co-occurring active TB), 
Gonzalez-Curiel et al. measured the gene expression of AMPs in peripheral blood 
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samples of all subjects. The study found decreased levels of gene expression for AMPs in 
subjects with co-occurring diabetes and LTBI compared to subjects with LTBI only[47]. 
Since AMPs are known to function in the killing of engulfed or invasive bacteria[47], a 
decreased level of AMPs may put individuals with co-occurring diabetes and LTBI at a 
higher risk of reactivation to active TB. 
Interestingly, some studies have suggested that the severity of diabetes, either by 
amount of complications or by poor glycemic control, increases the risk of TB. Studies 
have shown a relationship between HbA1c and blood glucose levels and the immune 
response to TB[9]. In a 2012 prospective cohort study conducted by Baker et al., a 
patient’s risk of TB was found to increase as the number of diabetes-related 
complications increased, with a three-fold risk of TB being seen among patients with two 
or more complications (OR 3.45; 95%CI 1.59-7.50)[4]. In a cohort study of 123,546 
individuals who participated in a community-based health screening service in northern 
Taiwan from 2005 to 2008, Lee et al. measured glycemic control using fasting plasma 
glucose (FPG) and determined occurrence of TB during a follow-up period up until 
December 2012. Researchers found that patients with diabetes who had poor glycemic 
control (categorized by a FPG>130mg/dL) had a significantly higher hazard of TB (aHR 
2.21; 95%CI 1.63-2.99) compared to patients without diabetes; however, the hazard of 
TB among patients with diabetes with good glycemic control (categorized by a 
FPG≤130mg/dL) was similar to the hazard of TB among patients without diabetes (aHR 
0.69; 95%CI 0.35-1.36). Lee et al. also conducted a linear-dose response analysis to 
determine if the hazard of TB increased with an increase in FPG and found the hazard of 
TB to slightly increase with increased FPG (aHR 1.06 per 10mg/dL increase in FPG; 
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95%CI 1.03-1.08)[48]. Other studies have also found higher HbA1c levels to be 
associated with a higher risk of developing TB[13, 49, 50].  
In addition to increasing the risk of reactivation of LTBI to active TB, co-
occurring diabetes also increases the likeliness of poor TB treatment outcomes, including 
treatment failure, relapse, and even death[6, 10, 11]. Patients with both diabetes and 
active TB generally present with symptoms consistent with more severe clinical 
manifestations, including higher smear grade and more lung cavities[51]. In a 
retrospective cohort study conducted among TB cases in Georgia, Magee et al. found 
patients with co-occurring diabetes and TB to be more likely to have cavitary lung 
disease at the time of TB diagnosis (51%) compared to both patients with co-occurring 
HIV and TB and patients with only TB – 19.9% and 34.7%, respectively. However, 
contradictory to other studies that have reported an increased risk of mortality among 
patients with co-occurring diabetes and TB[52], Magee et al. found that diabetes was not 
associated with increased mortality (aOR 1.05; 95%CI 0.60-1.84)[53]. 
The association between diabetes and TB has been known about for centuries and 
was even suggested during Roman times[11]. Studies have demonstrated a significant 
association between LTBI and active TB and diabetes. In a 2011 cross-sectional study 
conducted by Hensel et al., newly arrived refugees at a health clinic in Atlanta, Georgia 
were screened for diabetes, pre-diabetes and LTBI. Researchers determined diabetes and 
pre-diabetes by measuring HbA1c (glycated hemoglobin) levels and screened for LTBI 
using QFT-GIT. The prevalence of LTBI among patients with diabetes (43.4%) and pre-
diabetes (39.1%) was found to be significantly higher (p<0.01) than among patients 
without diabetes (25.9%). Hensel et al. hypothesized that the reason for a higher 
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prevalence of LTBI among patients with diabetes may be due to dysglycemia causing 
immunologic dysfunction[19]. 
 In a cohort study conducted in the country of Georgia during 2011-2014, Magee 
et al. evaluated 318 new TB patients (with no previous history of TB) for diabetes and 
pre-diabetes using HbA1c measurements. Researchers found the prevalence of diabetes 
and pre-diabetes to be fairly high among the new TB patients – 11.6% and 16.4%, 
respectively. The total combined prevalence of new TB patients with diabetes or pre-
diabetes was determined to be 28%[54].  
In a systematic review of 13 observational studies of the association between 
diabetes and active TB, Jeon et al. reported that all 13 studies found diabetes to be 
associated with an increased risk of TB. A meta-analysis of the results of the three cohort 
studies found the relative risk of TB among patients with diabetes to be 3.11 (95%CI 
2.27-4.26) times the relative risk among patients without diabetes[16]. Contradicting 
results were seen in a 2011 case-control study conducted in Denmark by Leegard et al. 
Researchers found the odds of active TB among patients with diabetes to only be 1.18 
(95%CI 0.96-1.45) times the odds of active TB among patients without diabetes. This 
finding of only a “modestly increased” risk of TB in patients with diabetes may be due to 
the study being conducted in Denmark, a country with a low burden of TB[13]. Though 
many studies have shown an association between active TB and diabetes, there is an 
extreme lack of studies on the association between LTBI and diabetes. 
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2.4 Summary of Literature Review 
  Highlights from the literature review of previous studies include: 
 Immune dysfunction associated with co-occurring diabetes and LTBI 
increases the risk of progression to active TB 
 Poor glycemic control (higher HbA1c levels) may be associated with an 
increased risk of TB 
 It has been well-established that active TB is associated with diabetes, but 
there are is a lack of studies investigating the association between LTBI 
and diabetes     
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CHAPTER III 
MANUSCRIPT 
Introduction 
 There were an estimated 10.4 million incident cases of active tuberculosis (TB) globally 
in 2015, and 1.4 million deaths attributable to TB[1]. In addition, about one-fourth of the global 
population has prevalent latent tuberculosis infection (LTBI)[55]. Although the lifetime risk of 
reactivation of LTBI to TB disease only occurs in approximately 10% of infected individuals [2], 
the risk of progression to TB is higher in individuals with comorbidities, such as HIV[5] and 
diabetes mellitus[6-9, 11, 19, 45]. Individuals with diabetes have approximately three times the 
risk of active TB compared to the general population[6, 7, 9, 10]. As a consequence of this 
increased risk of active TB, an estimated 15% of TB cases are attributed to diabetes[7, 15].  
 Of public health concern, the global diabetes epidemic is steadily increasing[6, 11, 12]. In 
2014, an estimated 415 million adults were living with diabetes, and the prevalence of diabetes is 
projected to reach 642 million adults globally by 2040[14]. Additionally, an estimated 95% of 
TB patients reside in low- and middle-income countries, and the largest projected increases in 
diabetes will occur in these same countries[11, 12].  
 Although existing evidence has demonstrated a relationship between diabetes and active 
TB, it is unclear whether diabetes also increases the risk of LTBI. The limited studies that 
examined the relationship between diabetes and LTBI have reported substantial heterogeneity 
across studies[56] and have not accounted for confounding by other clinical comorbidities such 
as kidney disease or hepatitis[18, 57]. Previous studies that reported a significant association 
between diabetes and LTBI were not widely generalizable and mostly have not used reliable 
measures of diabetes and LTBI[56]. Knowledge on the direction of the association between 
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diabetes and LTBI is also lacking. An increased risk of LTBI in patients with diabetes would 
have major clinical implications for TB and diabetes, especially with the expected increase in 
global diabetes prevalence. To address the gap in knowledge related to diabetes and LTBI, we 
aimed to determine the association between prediabetes and diabetes and LTBI using the 
National Health and Nutrition Examination Survey (NHANES), a study with data that are 
representative of the US population.  
Methods 
We conducted a cross-sectional study using data collected as part of the NHANES 2011-
2012 cycle, which is the most recent cycle that includes the QuantiFERON®-TB Gold In Tube 
(QFT-GIT) test as a measure of LTBI status. Briefly, NHANES is a nationally representative 
survey of US non-institutionalized civilians that includes an in-person home interview followed 
by a health examination. Details of NHANES methodology have been published previously[58]. 
In the 2011-2012 survey cycle, a total of 13,431 individuals were selected for participation from 
30 different locations in the United States. Of those individuals, 9,756 completed the in-person 
home interview and 9,338 completed the in-person home interview and received the health 
examination[59]. 
Study Design and Participants 
 Eligible participants for our study were adults aged 20 years and older who completed the 
home questionnaire and the health examination. Eligible participants were also required to have 
both a valid TB test result and a valid diabetes status. A positive or negative result for the QFT-
GIT test was considered a valid result. Participants who were missing a result for the QFT-GIT 
test or who had an indeterminate result for the test were excluded from the study. Participants 
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who had a glycated hemoglobin (HbA1c) measurement and/or information regarding self-
reported diabetes status were considered to have a valid diabetes status. Participants who were 
missing both an HbA1c measurement and information regarding self-reported diabetes status 
were excluded from the study. 
 Biological specimen collection was performed in specially equipped mobile examination 
centers (MECs)[58]. Blood samples were drawn by a phlebotomist and refrigerated or frozen 
before being shipped and urine samples were also collected from participants.  Samples were 
transported to laboratories across the United States for processing[60], except samples for QFT-
GIT testing, which were sent to only one Clinical Laboratory Improvement Act-certified 
laboratory for processing[18].  
Study Measures and Definitions  
 Diabetes status of participants was defined by self-reported diabetes status and HbA1c 
levels. Participants who indicated that they had previously been diagnosed by a healthcare 
professional to have diabetes were classified as having diabetes regardless of HbA1c 
measurement. If participants did not indicate a previous history of diabetes diagnosis, diabetes 
status was then classified by HbA1c as no diabetes (≤5.6%), prediabetes (5.7-6.4%), or diabetes 
(≥6.5%) according to the American Diabetes Association guidelines[61]. Participants with 
diabetes were further classified as having diagnosed or undiagnosed diabetes. Diagnosed 
diabetes was classified as self-reporting diabetes, and undiagnosed diabetes was classified as 
self-reporting not having diabetes but having an HbA1c level in the range for diabetes (≥6.5%). 
Among participants with self-reported diabetes, length of time since initial diabetes diagnosis 
and information regarding diabetes medication were also assessed via questionnaire. Use of 
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diabetes medications was determined by responses to self-reported questions on the use of 
insulin and oral agents[62]. 
 Latent TB infection was defined by QFT-GIT according to manufacturer instructions. 
Results were interpreted according to guidelines from the Centers for Disease Control and 
Prevention (CDC) for using interferon-gamma release assays (IGRAs)[63]. Participants with a 
positive QFT-GIT result were classified as LTBI positive, participants with a negative QFT-GIT 
result were classified as LTBI negative, and participants with an indeterminate QFT-GIT result 
were classified as missing.  
 Participants who self-reported they had ever been told by a health care professional to 
have active TB were defined as having a history of active TB. Body mass index (BMI) ranges 
were categorized as underweight (<18.5), normal weight (18.5-24.9 kg/m2), overweight (25.0-
29.9 kg/m2), or obese (≥30 kg/m2) according to CDC guidelines[64]. Age ranges were 
categorized as young adult (20-34 years), middle-aged (35-64 years), or elderly (65 years and 
older). Current smokers were defined as participants who self-reported use of 100 cigarettes in 
their lifetime and self-reported currently smoking. Former smokers were defined as those who 
reported smoking 100 cigarettes in their lifetime but did not currently smoke cigarettes. 
Participants who had not smoked 100 cigarettes in their lifetime were defined as never smokers 
[65, 66].  
Urine samples were analyzed for albumin creatinine ratio (ACR), and ACR levels were 
categorized as normal to mildly increased (<30mg/g), moderately increased (30-300mg/g), or 
severely increased (>300mg/g) according to National Kidney Foundation guidelines for 
albuminuria categories in chronic kidney disease[67]. Hepatitis B virus (HBV) core antibody 
(anti-HBc) and surface antigen (HBsAg) response were determined using the VITROS Anti-HBc 
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assay and HBsAg assay, respectively; results were defined as positive or negative. The HBsAg 
assay was only performed for participants that tested positive for anti-HBc; participants with a 
negative result for anti-HBc were defined as negative for HBsAg. Hepatitis C antibody (anti-
HCV) response was determined using the VITROS Anti-HCV assay; results were defined as 
positive or negative. Non-fasting blood samples were analyzed for total cholesterol and high-
density lipoprotein (HDL) cholesterol[68]. Our study categorized total cholesterol levels as 
desirable (<200mg/dL), borderline high (200-239mg/dL), or high (≥240mg/dL) according to 
National Institutes of Health guidelines[69]. Our study categorized HDL cholesterol levels as 
major risk factor for heart disease (<40mg/dL), borderline (40-59mg/dL), or protective against 
heart disease (≥60mg/dL) according to Medline Plus guidelines[70]. Responses of “don’t know” 
or “refused” were recoded as missing for all variables. 
Statistical Analyses 
To examine the association between diabetes and LTBI we used bivariate analyses and 
multivariable logistic regression. The Rao-Scott chi-square test was used to analyze all bivariate 
associations between participant characteristics and LTBI and diabetes. To examine the 
prevalence of diabetes and LTBI in the United States population, we reported weighted 
prevalence estimates and 95% confidence intervals (CI). Taylor series method was used to 
estimate variance for all prevalence estimates[71]. Multivariable logistic regression models were 
used to estimate the adjusted odds ratio (aOR) and 95% CI between diabetes and LTBI and were 
adjusted for potential confounders. Covariates included in multivariable models as confounders 
were chosen from observed bivariate associations with diabetes and LTBI, previous study 
findings, and causal model theory (directed acyclic graphs) [72]. In multivariable models, 
multiplicative statistical interaction was assessed to determine if the association between diabetes 
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and LTBI was modified by obesity or HDL cholesterol. In a subgroup analysis, we also 
examined the bivariate association between participant characteristics and LTBI only among 
individuals with diabetes. All analyses were performed using SAS version 9.4 and accounted for 
the weighted stratified probability sample design of NHANES using SAS survey procedures[73]. 
Because medical examination data were used during the analyses, we used the weight variable 
WTMEC2YR to obtain accurate prevalence estimates and measures of association. A two-sided 
p-value <0.05 was considered statistically significant for all tests. 
Sensitivity Analysis  
 We performed sensitivity analyses to assess potential error due to 1) misclassification of 
diabetes status and 2) covariate misspecification in multivariable models. To assess diabetes 
misclassification, we re-examined the diabetes-LTBI association after adding fasting blood 
glucose (prediabetes 100-125mg/dL, or diabetes ≥126mg/dL) to our primary diabetes definition 
which used self-report and HbA1c only[61]. In the second sensitivity analysis we specified 
several subsets of adjusted multivariable models to provide a range of plausible aORs and 
95%CI for the association between diabetes and LTBI. 
Results 
Study Participants 
 Of 9,756 NHANES 2011-2012 participants, 5,560 (57.0%) were aged 20 years or older 
and thus eligible for our study. A total of 4,958 (89.2%) participants had both valid QFT-GIT 
results and information on self-reported diabetes status and/or HbA1c results and were included 
in these analyses (Figure 1). Before accounting for selection weights, 793 eligible participants 
had diabetes, 513 had LTBI, and 127 had both diabetes and LTBI. 
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Prevalence of Diabetes and Latent TB Infection 
 The estimated prevalence of diabetes among adults in the United States population was 
11.4% (95%CI 9.8-13.0%) and the prevalence of prediabetes was 22.1% (95%CI 20.5-23.8%) 
(Table 1). The prevalence of diabetes was highest among the elderly (22.9%; 95%CI 19.8-
25.9%),  people with obesity (20.4%; 95%CI 17.3-23.5%), those with less than a 9th grade 
education (25.2%; 95%CI 18.2-32.2%), severely increased ACRs (46.9%; 95%CI 33.7-60.1%), 
hepatitis C (19.8%; 95%CI 7.1-32.5%), and hypertension (23.3%; 95%CI 20.8-25.9%).   
 Our results estimated that the prevalence of LTBI among adults in the United States was 
5.9% (95%CI 4.9-7.0%) (Table 2). Prevalence of LTBI was highest among the elderly (8.8%; 
95%CI 6.6-10.9%), the foreign-born (17.2%; 95%CI 14.3-20.0%), those with less than a 9th 
grade education (17.9%; 95%CI 13.2-22.7%), Hispanics (12.9%; 95%CI 10.4-15.4%),non-
Hispanic Asians (20.3%; 95%CI 16.8-23.8%), and those who reported a previous history of 
active TB (42.7%; 95%CI 24.1-61.2). LTBI prevalence was also high among those with high 
(>300mg/g) ACR (12.9%; 95%CI 6.7-19.2%), those who tested positive for anti-HBc (18.0%; 
95%CI 11.6-24.4%), and those who tested positive for HBsAg (23.0%; 95%CI 8.2-37.7%). 
The prevalence of LTBI was significantly higher among adults with diabetes (11.6%; 
95%CI 7.9-15.3%) compared to those without diabetes (4.6%; 95%CI 3.7-5.6%). LTBI 
prevalence was also higher among those with prediabetes (7.0%; 95%CI 5.2-8.7%) compared to 
those without diabetes, though the difference was not statistically significant. Adults with 
diabetes and prediabetes had significantly higher crude odds of LTBI (diabetes: crude OR 2.70; 
95%CI 1.76-4.14; prediabetes: crude OR 1.54; 95%CI 1.24-1.91) compared to those without 
diabetes (Table 3). Reported inversely, among those with LTBI the prevalence of diabetes was 
22.2% (95%CI 16.6-27.8%) and the prevalence of prediabetes was 25.9% (95%CI 22.1-29.7%). 
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Among those without LTBI the prevalence of diabetes was 10.7% (95%CI 9.0-12.4%) and the 
prevalence of prediabetes was 21.9% (95%CI 20.3-23.6%). 
Multivariable Models Results 
 Multivariable logistic models were examined adjusting for age, sex, smoking status, 
history of active TB, and foreign born status. Adults with diabetes had significantly higher odds 
of LTBI (aOR 1.90; 95%CI 1.15-3.14) compared to adults without diabetes (Table 3). Those 
previously diagnosed with diabetes had significantly higher odds of LTBI (aOR 1.75; 95%CI 
1.09-2.80) compared to adults without diabetes, as did adults with previously undiagnosed 
diabetes (aOR 1.96; 95%CI 1.05-3.68). The odds of LTBI among adults with prediabetes (aOR 
1.15; 95%CI 0.90-1.47) was not significantly higher than among adults without diabetes.   
 We found no indication of significant multiplicative interaction. Although not 
significantly different from each other, the association between diabetes and LTBI tended to be 
greater among those with obesity (aOR 2.22; 95%CI 1.08-4.54) compared to those without 
obesity (aOR 1.48; 95%CI 0.85-2.58) (data not shown). Similarly, the association between 
diabetes and LTBI was non-significantly greater among those with higher HDL (≥60mg/dL) 
levels (aOR 2.77; 95%CI 1.13-6.84) compared to those with lower HDL (<60mg/dL) levels 
(aOR 1.80; 95%CI 0.99-3.29). 
Subgroup Analysis of Adults with Diabetes 
 Among adults with diabetes, an estimated 19.9% (95%CI 15.3-24.4%) were previously 
undiagnosed (Table 4). Prevalence of LTBI was non-significantly (p-value=0.24) different 
among adults with previously undiagnosed diabetes (14.4%; 95%CI 6.7-22.2%) compared to 
adults who had been previously diagnosed (10.9%; 95%CI 7.4-14.4%). LTBI prevalence was 
 
 
25 
 
significantly higher (p-value=0.03) among adults who reported not using insulin (12.9%; 95%CI 
8.5-17.3%) compared to adults who reported using insulin (7.3%; 95%CI 3.1-11.4). Among 
those with diabetes, LTBI prevalence was found to be highest among Hispanics (24.3%; 95%CI 
12.4-36.2%), non-Hispanic Asians (27.5%; 95%CI 19.0-35.9%), those born outside of the United 
States (30.2; 95%CI 18.8-41.6%), and those with a positive test result for anti-HBc (20.8%; 
95%CI 8.9-32.7%). 
Sensitivity Analyses 
 In our sensitivity analysis to assess potential misclassification of diabetes using FBG in 
addition to self-report and HbA1c, adults with diabetes had significantly higher crude odds of 
LTBI (crude OR 2.43; 95%CI 1.32-4.49) compared to those without diabetes (data not shown). 
Adults with prediabetes had non-significantly higher crude odds of LTBI (crude OR 1.21; 
95%CI 0.74-2.00) compared to those without diabetes. After adjusting for age, sex, smoking 
status, history of active TB, and foreign born status, adults with diabetes had a non-significant 
higher odds of LTBI (aOR 1.36; 95%CI 0.70-2.65) compared to those without diabetes.  
 In our sensitivity analysis to assess covariate misspecification of adjusted models, we found 
adjusted odds ratios that ranged from 1.49 (95%CI 0.83-2.68) to 2.20 (95%CI 1.22-3.96) for the 
odds of LTBI in adults with diabetes compared to those without diabetes (Supplemental Table 
1). We found adjusted odds ratios that ranged from 0.95 (95%CI 0.75-1.21) to 1.25 (95%CI 
0.93-1.68) for the odds of LTBI in adults with prediabetes compared to those without diabetes; 
however, none were statistically significant. 
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Discussion 
We used data nationally representative of the US population to examine the association 
between LTBI and diabetes and found a robust relationship between the two diseases. We 
reported that the prevalence of LTBI among adults with diabetes was more than twice the 
prevalence of those without diabetes. Similarly, we found that more than one-fifth of adults with 
LTBI had diabetes. We did not find significant differences in LTBI prevalence among those who 
were previously diagnosed compared to those who were previously undiagnosed. We also did 
not find significant differences in LTBI prevalence among those with prediabetes compared to 
those without diabetes. To our knowledge, this study is the largest and most generalizable 
analysis to compare the prevalence of LTBI among adults with and without diabetes and 
prediabetes.  
Our results are consistent with the findings of previous studies. In a systematic review 
conducted by Lee et al., the meta-analysis included findings from one cohort study and 12 cross-
sectional studies investigating the association between diabetes and LTBI. From the 12 cross-
sectional studies, researchers calculated a pooled odds ratio of 1.18 (95%CI 1.06-1.30), 
indicating a slight yet significant increased odds of LTBI among patients with diabetes compared 
to patients without diabetes[56]. A limitation of several studies reviewed in Lee et al.’s 
systematic review and meta-analysis was the potential misclassification of LTBI due to 
measurement error associated with the TST (tuberculin skin test). Unlike many previous studies, 
our study relied upon the use of QFT-GIT which is not affected by the Bacillus Calmette-Guérin 
(BCG) vaccine. Our national estimates of LTBI prevalence were similar to previously reported 
estimates[18, 28] 
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Our results were similar to a study conducted by Hensel et al. in the metropolitan area of 
Atlanta, Georgia[19]. This study also utilized both HbA1c and QFT-GIT to determine diabetes 
status and LTBI status, respectively. Hensel et al. found a nearly doubled prevalence of LTBI 
among patients with diabetes compared to those without diabetes[19]. Unlike our study, 
however, the Atlanta study was not generalizable to the US adult population, as it only included 
recently arrived refugees to the United States[19]. As with the Atlanta study, we found no 
significant difference in the prevalence of LTBI among patients with previously undiagnosed 
diabetes compared to those with previously diagnosed diabetes[19]. 
Although the causal mechanisms that result in increased co-occurrence of LTBI and 
diabetes remain to be definitively established, there are relevant biologic hypotheses that may 
explain how LTBI may increase the risk of diabetes and vice-versa. Some LTBI granulomas on 
the spectrum of high MTB activity include bacterial replication and likely result in proximal 
immune signaling, a phenomena which may persist in adipose tissue[74]. Secretion of pro-
inflammatory adipokines and cytokines within adipocytes could interfere with insulin regulation 
and contribute to diabetes risk[30, 75]. If LTBI contributes to immune activation within visceral 
adipose tissue, it would likely increase the risk of diabetes or prediabetes. Alternatively, chronic 
low-grade inflammation and immunopathology associated with diabetes and prediabetes [31, 33] 
may contribute to susceptibility to TB infection[8, 9].  
 Our study was subject to several limitations. First, there may have been misclassification 
of participant characteristics. For example, self-reported information on smoking status was 
determined via participant responses to a questionnaire, so smokers may have reported not 
smoking due to social stigma. While diabetes and LTBI status may also be subject to 
misclassification, we defined these primary study variables using currently recommended 
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clinical measures (HbA1c and QFT-GIT)[76, 77]. By using the QFT-GITs instead of the TST to 
measure LTBI, we avoided potential cross-reaction with antigens found in the BCG vaccine, 
commonly used outside the United States [29, 77]. However, we did not account for discordance 
between QFT-GIT and TST, and therefore some misclassification of LTBI may have occurred. 
Second, in this study we were unable to adjust for the probability being exposed to someone with 
active TB. Although previous history of active TB was assessed via questionnaire and found to 
be associated with LTBI but not diabetes status, the inability to adjust for probability of exposure 
to TB may have distorted our estimated association between LTBI and diabetes. Nonetheless, we 
did adjust for several other key confounding factors such as smoking, age, and foreign born 
status. We also were able to assess the distribution of other underlying infections, such as 
hepatitis B and C and kidney disease, and found no evidence of confounding. Third, our study 
was a cross-sectional design, and as such we were unable to determine the temporal relationship 
between LTBI and diabetes. For example, our results are unable to differentiate whether the 
observed association was due to an increased risk of LTBI from diabetes or if LTBI may increase 
the risk of diabetes. Longitudinal studies are needed to investigate the temporal association 
between LTBI and diabetes. 
Conclusion 
 This study reported that diabetes was significantly associated with an increased odds of 
LTBI prevalence in US adults, even after adjusting for key confounding factors. Overall, more 
than one-fifth of all adults with LTBI had diabetes. Information from this study greatly improves 
our understanding of the intersection of the TB and diabetes epidemics. With the increasing 
prevalence of diabetes in areas with the highest burden of TB, targeted efforts may be needed to 
address the co-infection of diabetes and LTBI to prevent an increase in TB incidence worldwide. 
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Table 1: Weighted prevalence of diabetes and prediabetes among the civilian, non-institutionalized 
United States population, adults 20 years and older, 2011-2012 
Participant 
Characteristics 
Totals for 
Population 
N=4,958 
% (95% CI) 
Diabetes1 
% (95% CI) 
11.4 
(9.8-13.0) 
Prediabetes2 
% (95% CI) 
22.1 
(20.5-23.8) 
No Diabetes 
% (95% CI) 
66.5 
(64.2-68.8) 
p-
value3 
Age (years) 
   20 – 34 
   35 – 64 
   ≥65 
 
27.5 (23.1-31.9) 
54.9 (51.8-57.9) 
17.6 (15.3-19.9) 
 
2.0 (1.2-2.8) 
12.4 (10.2-14.6) 
22.9 (19.8-25.9) 
 
9.0 (7.3-10.7) 
24.0 (20.6-27.3) 
36.9 (32.8-41.0) 
 
89.0 (87.0-91.0) 
63.6 (60.0-67.1) 
40.3 (34.8-45.7) 
 
<0.01 
BMI4 
   <18.5 
   18.5 – 24.9 
   25.0-29.9 
   ≥30.0 
 
1.8 (1.3-2.2) 
29.4 (26.1-32.6) 
33.5 (30.7-36.3) 
35.4 (32.3-38.5) 
 
4.2 (0-8.8) 
5.1 (3.4-6.9) 
7.7 (6.7-8.6) 
20.4 (17.3-23.5) 
 
8.0 (2.1-13.9) 
17.6 (14.0-21.2) 
22.8 (19.2-26.3) 
26.1 (23.1-29.1) 
 
87.8 (81.0-94.5) 
77.3 (72.9-81.7) 
69.6 (66.1-73.0) 
53.5 (49.3-57.6) 
 
<0.01 
Foreign Born5 
   No 
   Yes 
 
82.1 (77.9-86.3) 
17.9 (13.7-22.1) 
 
11.0 (9.2-12.8) 
13.2 (11.3-15.0) 
 
22.0 (20.0-23.9) 
22.7 (19.8-25.6) 
 
67.0 (64.4-69.6) 
64.1 (61.1-67.1) 
 
0.12 
LTBI6 
   Positive 
   Negative 
 
5.9 (4.9-7.0) 
94.1 (93.0-95.1) 
 
22.2 (16.6-27.8) 
10.7 (9.0-12.4) 
 
25.9 (22.1-29.7) 
21.9 (20.3-23.6) 
 
51.9 (45.8-58.0) 
67.4 (65.0-69.8) 
 
<0.01 
TST7 
   Positive 
   Negative 
 
4.7 (3.0-6.4) 
95.3 (93.6-97.0) 
 
15.5 (9.4-21.6) 
11.3 (9.7-13.0) 
 
29.2 (18.5-39.9) 
22.2 (20.2-24.2) 
 
55.3 (46.6-63.9) 
66.5 (64.0-69.9) 
 
0.11 
HbA1c (%)8 
   <5.7 
   5.7-6.4 
   ≥6.5 
 
67.1 (64.9-69.3) 
24.8 (22.7-26.9) 
8.1 (6.9-9.3) 
 
0.91 (0.50-1.3) 
10.8 (7.8-13.8) 
100 (100-100) 
 
0 (0-0) 
89.2 (86.2-92.2) 
0 (0-0) 
 
99.1 (98.7-99.5) 
0 (0-0) 
0 (0-0) 
 
Education 
   <9th Grade 
   9th – 12th  
   HS Grad/GED 
   Some College 
   ≥College Grad 
 
5.7 (4.5-7.0) 
10.5 (7.6-13.5) 
20.2 (17.2-23.2) 
32.2 (29.0-35.3) 
31.4 (26.1-36.7) 
 
25.2 (18.2-32.2) 
15.0 (13.5-16.5) 
14.7 (11.1-18.2) 
10.0 (8.3-11.7) 
7.0 (4.2-9.8) 
 
29.2 (24.0-34.4) 
26.6 (21.9-31.2) 
27.2 (21.1-33.2) 
20.7 (17.0-24.5) 
17.5 (14.2-20.8) 
 
45.6 (39.3-52.0) 
58.4 (53.7-63.1) 
58.2 (52.1-64.2) 
69.3 (66.1-72.5) 
75.5 (70.9-80.1) 
 
<0.01 
Race/Ethnicity 
    
   Hispanic 
   NH White 
   NH Black 
   NH Asian 
    
 
14.7 (9.2-20.2) 
68.8 (60.2-77.3) 
11.3 (6.5-16.1) 
5.2 (3.2-7.1) 
 
 
13.1 (10.5-15.6) 
9.4 (7.6-11.2) 
17.9 (14.2-21.6) 
12.9 (9.8-16.0) 
 
 
21.8 (19.2-24.3) 
20.9 (18.4-23.5) 
30.0 (27.1-32.9) 
22.9 (18.3-27.5) 
 
 
65.1 (62.1-68.2) 
69.6 (66.2-73.1) 
52.1 (48.7-55.6) 
64.2 (57.4-71.0) 
 
 
<0.01 
Sex 
   Female 
   Male 
 
52.2 (50.5-53.9) 
47.8 (46.1-49.5) 
 
11.1 (9.3-12.8) 
11.8 (9.7-13.8) 
 
22.2 (19.7-24.8) 
22.0 (20.0-24.0) 
 
66.7 (63.5-69.9) 
66.3 (63.3-69.2) 
 
0.82 
Smoking Status9 
   Current 
   Former 
   Never 
 
19.5 (17.2-21.7) 
24.3 (21.6-26.9) 
56.2 (53.3-59.1) 
 
10.5 (8.8-12.3) 
15.2 (11.7-18.8) 
10.2 (8.2-12.2) 
 
27.1 (21.4-32.8) 
23.6 (20.2-26.9) 
20.0 (17.4-22.7) 
 
62.4 (57.0-67.7) 
61.2 (56.3-66.1) 
69.8 (66.6-73.0) 
 
<0.01 
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Previous TB10 
   Yes 
   No 
 
0.40 (0.22-0.58) 
99.6 (99.4-99.8) 
 
7.3 (0-16.3) 
11.4 (9.8-13.0) 
 
30.8 (14.2-47.4) 
22.1 (20.4-23.8) 
 
61.9 (45.0-78.8) 
66.5 (64.1-68.8) 
 
0.59 
TB Meds11 
   Yes 
   No 
 
0.24 (0.12-0.36) 
99.8 (99.6-99.9) 
 
4.7 (0-12.2) 
11.4 (9.8-13.0) 
 
32.8 (4.4-61.2) 
22.1 (20.4-23.8) 
 
62.5 (32.5-92.5) 
66.5 (64.1-68.8) 
 
0.63 
Ratio of Family Income 
to Poverty12 
  0-0.99 
   1-1.99 
   2-2.99 
   3-3.99 
   4-4.99 
   ≥5 
 
 
17.2 (13.8-20.6) 
21.1 (18.1-24.2) 
14.3 (12.1-16.4) 
12.1 (9.1-15.1) 
10.7 (8.5-12.9) 
24.6 (19.6-29.6) 
 
 
14.9 (11.6-18.1) 
14.9 (12.3-17.5) 
11.9 (7.9-15.8) 
9.4 (7.2-11.6) 
13.6 (5.6-21.5) 
5.4 (3.0-7.8) 
 
 
20.5 (15.6-25.3) 
24.6 (20.4-28.8) 
24.0 (19.1-28.9) 
18.5 (14.6-22.4) 
17.8 (13.3-22.2) 
21.5 (17.2-25.9) 
 
 
64.7 (57.9-71.5) 
60.5 (55.3-65.7) 
64.1 (57.8-70.5) 
72.1 (67.7-76.6) 
68.7 (60.0-77.3) 
73.1 (67.1-79.0) 
 
 
 
<0.01 
Albumin/Creatinine 
Ratio (mg/g)13 
   <30 
   30 – 300 
   >300 
 
 
90.4 (89.2-91.6) 
8.3 (7.4-9.2) 
1.3 (0.94-1.7) 
 
 
9.2 (7.9-10.5) 
28.7 (23.5-33.9) 
46.9 (33.7-60.1) 
 
 
21.9 (20.1-23.8) 
24.8 (22.4-27.1) 
21.0 (8.6-33.3) 
 
 
68.9 (66.6-71.2) 
46.5 (40.5-52.5) 
32.1 (16.2-48.1) 
 
 
<0.01 
HepB Core Ab14 
   Positive 
   Negative 
 
4.6 (3.6-5.5) 
95.4 (94.5-96.4) 
 
19.1 (13.1-25.1) 
10.8 (9.3-12.3) 
 
28.0 (20.3-35.7) 
21.7 (19.9-23.6) 
 
52.9 (46.2-59.6) 
67.5 (65.2-69.8) 
 
<0.01 
HepB Surface Ag15 
   Positive 
   Negative 
 
0.34 (0.20-0.48) 
99.7 (99.5-99.8) 
 
8.6 (1.4-15.8) 
11.2 (9.7-12.7) 
 
27.7 (12.9-42.4) 
22.0 (20.3-23.7) 
 
63.8 (45.9-81.6) 
66.9 (64.6-69.1) 
 
<0.01 
HepC Ab (confirmed)16 
   Positive 
   Negative 
 
1.7 (1.0-2.3) 
98.3 (97.7-99.0) 
 
19.8 (7.1-32.5) 
11.1 (9.7-12.5) 
 
17.5 (11.4-23.6) 
22.0 (20.2-23.9) 
 
62.7 (46.9-78.4) 
66.9 (64.6-69.2) 
 
0.01 
Self-reported 
Hypertension17 
   Yes 
   No 
 
 
31.5 (28.4-34.7) 
68.5 (65.3-71.6) 
 
 
23.3 (20.8-25.9) 
5.9 (4.8-7.0) 
 
 
29.2 (26.6-31.8) 
18.9 (17.2-20.6) 
 
 
47.5 (44.1-50.8) 
75.2 (73.2-77.3) 
 
 
<0.01 
Total Bilirubin 
(mg/dL)18 
   Normal 
   Not Normal 
 
 
98.7 (98.0-99.4) 
1.3 (0.59-2.0) 
 
 
11.2 (9.6-12.7) 
5.3 (0.21-10.4) 
 
 
22.1 (20.5-23.7) 
14.3 (1.7-26.9) 
 
 
66.7 (64.4-69.1) 
80.4 (67.0-93.9) 
 
 
0.11 
Total Cholesterol 
(mg/dL)19 
   <200 
   200-239 
   ≥240 
 
 
56.9 (55.0-58.8) 
30.1 (28.4-31.7) 
13.0 (11.4-14.7) 
 
 
12.7 (11.2-14.1) 
8.9 (6.6-11.3) 
9.6 (6.4-12.9) 
 
 
19.1 (17.0-21.2) 
24.4 (20.8-28.1) 
29.2 (24.9-33.7) 
 
 
68.2 (65.4-71.0) 
66.6 (61.9-71.3) 
61.1 (56.1-66.1) 
 
 
<0.01 
HDL Cholesterol 
(mg/dL)20 
   <40 
   40 – 59 
   ≥60 
 
 
17.4 (14.7-20.1) 
54.7 (51.9-57.6) 
27.9 (25.5-30.2) 
 
 
18.9 (13.4-24.5) 
11.8 (10.5-13.1) 
5.1 (3.2-6.9) 
 
 
25.4 (22.2-28.6) 
23.3 (21.1-25.5) 
17.5 (13.4-21.6) 
 
 
55.7 (48.6-62.7) 
64.9 (62.3-67.5) 
77.4 (72.7-82.1) 
 
 
<0.01 
Table 1 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-
tuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core 
antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody 
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1: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that 
he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who self-reported 
diabetes were classified as having diabetes regardless of HbA1c. 
2: Prediabetes determined according to American Diabetes Association guidelines[61]. 
3: All p-values obtained using Rao-Scott chi-square. 
4: BMI categories defined according to CDC guidelines[64]. 
5. Foreign born individuals include those who reported being born in one of the five United States territories. 
6: Positive LTBI defined by positive QFT-GIT result; negative LTBI defined by negative QFT-GIT result. 
7: Positive TST defined as an induration >10mm[78]. 
8: HbA1c categories determined according to American Diabetes Association guidelines[61]. 
9: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and 
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at 
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked 
at least 100 cigarettes in their lifetime defined as never having smoked[65, 66]. 
10: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?”[79]11: 
Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or 
TB?”; specific medicine type not asked[79]. 
12: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and 
Human Services used as poverty measure to calculate ratio of family income to poverty[80]. 
13: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for 
albuminaria categories in chronic kidney disease (CKD)[67]. 
14: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[81]. 
15 : HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by 
response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for 
HBsAg[81]. 
16: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with 
repeatedly positive reactions to Anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 
Strip[82]. 
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17: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had hypertension/high blood pressure)[83]. 
18: Categories for Total Bilirubin defined according to Medline Plus guidelines[84]. 
19: Categories for Total Cholesterol defined according to National Institute of Health guidelines[69]. 
20: Categories for HDL Cholesterol defined according to Medline Plus guidelines as follows[70]. 
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Table 2: Weighted prevalence of latent tuberculosis infection (LTBI) among the civilian, non-
institutionalized United States population, adults 20 years and older, 2011-2012 
Participant 
Characteristics 
 
Totals for 
Population 
N=4,958 
% (95% CI) 
LTBI Positive 1 
% (95% CI) 
5.9 
(4.9-7.0) 
LTBI Negative2 
% (95% CI) 
94.1 
(93.0-95.1) 
p-value3 
Age (years)  
   20 – 34 
   35 – 64 
   ≥65 
 
27.5 (23.1-31.9) 
54.9 (51.8-57.9) 
17.6 (15.3-19.9) 
 
3.3 (2.5-4.1) 
6.4 (4.7-8.1) 
8.8 (6.6-10.9) 
 
96.7 (95.9-97.5) 
93.6 (91.9-95.3) 
91.2 (89.1-93.4) 
 
<0.01 
BMI4 
   <18.5 
   18.5 – 24.9 
   25.0-29.9 
   ≥30.0 
 
1.8 (1.3-2.2) 
29.4 (26.1-32.6) 
33.5 (30.7-36.3) 
35.4 (32.3-38.5) 
 
7.9 (2.0-13.9) 
6.4 (4.5-8.3) 
5.6 (4.3-6.9) 
5.8 (4.7-7.0) 
 
92.1 (86.1-98.0) 
93.6 (91.7-95.5) 
94.4 (93.1-95.7) 
94.2 (93.0-95.3) 
 
0.68 
Foreign Born5 
   No 
   Yes 
 
82.1 (77.9-86.3) 
17.9 (13.7-22.1) 
 
3.5 (2.5-4.6) 
17.2 (14.3-20.0) 
 
96.5 (95.4-97.5) 
82.8 (80.0-85.7) 
 
<0.01 
 
TST6 
   Positive 
   Negative 
 
4.7 (3.0-6.4) 
95.3 (93.6-97.0) 
 
46.2 (40.1-52.4) 
3.6 (2.7-4.4) 
 
53.8 (47.6-59.9) 
96.4 (95.6-97.3) 
 
<0.01 
Diabetes7 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
66.5 (64.2-68.8) 
22.1 (20.5-23.8) 
11.4 (9.8-13.0) 
 
4.6 (3.7-5.6) 
7.0 (5.2-8.7) 
11.6 (7.9-15.3) 
 
95.4 (94.4-96.3) 
93.0 (91.3-94.8) 
88.4 (84.7-92.1) 
 
<0.01 
HbA1c (%)8   <5.7 
   5.7-6.4 
   ≥6.5 
 
67.1 (64.9-69.3) 
24.8 (22.7-26.9) 
8.1 (6.9-9.3) 
 
4.7 (3.7-5.6) 
7.7 (6.0-9.5) 
10.9 (7.1-14.8) 
 
95.3 (94.4-96.3) 
92.3 (90.5-94.0) 
89.1 (85.2-92.9) 
 
<0.01 
Education 
   <9th Grade 
   9th – 12th  
   HS Grad/GED 
   Some College 
   ≥College Grad 
 
5.7 (4.5-7.0) 
10.5 (7.6-13.5) 
20.2 (17.2-23.2) 
32.2 (29.0-35.3) 
31.4 (26.1-36.7) 
 
17.9 (13.2-22.7) 
7.7 (5.4-10.0) 
7.1 (4.7-9.5) 
3.5 (2.2-4.7) 
5.0 (3.4-6.6) 
 
82.1 (77.3-86.8) 
92.3 (90.0-94.6) 
92.9 (90.5-95.3) 
96.5 (95.3-97.8) 
95.0 (93.4-96.6) 
 
<0.01 
Race/Ethnicity 
   Hispanic 
   NH White 
   NH Black 
   NH Asian 
 
14.7 (9.2-20.2) 
68.8 (60.2-77.3) 
11.3 (6.5-16.1) 
5.2 (3.2-7.1) 
 
12.9 (10.4-15.4) 
3.1 (2.2-4.1) 
8.0 (6.0-9.9) 
20.3 (16.8-23.8) 
 
87.1 (84.6-89.6) 
96.9 (95.9-97.8) 
92.0 (90.1-94.0) 
79.7 (76.2-83.4) 
 
<0.01 
Sex 
   Female 
   Male 
 
52.2 (50.5-53.9) 
47.8 (46.1-49.5) 
 
5.0 (3.9-6.2) 
6.9 (5.7-8.2) 
 
95.0 (93.8-96.1) 
93.1 (91.8-94.3) 
 
<0.01 
Smoking Status9 
   Current 
   Former 
   Never 
 
19.5 (17.2-21.7) 
24.3 (21.6-26.9) 
56.2 (53.3-59.1) 
 
6.7 (4.3-9.1) 
7.1 (4.8-9.5) 
5.2 (4.2-6.1) 
 
93.3 (90.9-95.7) 
92.9 (90.5-95.2) 
94.8 (93.9-95.8) 
 
0.15 
Previous TB10     
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   Yes 
   No 
0.40 (0.22-0.58) 
99.6 (99.4-99.8) 
42.7 (24.1-61.2) 
5.8 (4.8-6.8) 
57.3 (38.8-75.9) 
94.2 (93.2-95.2) 
<0.01 
TB Meds11 
   Yes 
   No 
 
0.24 (0.12-0.36) 
99.8 (99.6-99.9) 
 
48.2 (24.6-71.7) 
5.8 (4.8-6.8) 
 
51.8 (28.3-75.4) 
94.2 (93.2-95.2) 
 
<0.01 
Ratio of Family Income 
to Poverty12 
   0-0.99 
   1-1.99 
   2-2.99 
   3-3.99 
   4-4.99 
   ≥5 
 
 
17.2 (13.8-20.6) 
21.1 (18.1-24.2) 
14.3 (12.1-16.4) 
12.1 (9.1-15.1) 
10.7 (8.5-12.9) 
24.6 (19.6-29.6) 
 
 
8.5 (6.3-10.7) 
7.8 (6.1-9.5) 
5.4 (2.3-8.5) 
4.7 (2.7-6.6) 
2.9 (0.94-4.9) 
4.1 (2.3-5.9) 
 
 
91.5 (89.3-93.7) 
92.2 (90.5-93.9) 
94.6 (91.5-97.7) 
95.3 (93.4-97.3) 
97.1 (95.1-99.1) 
95.9 (94.1-97.7) 
 
 
<0.01 
Albumin/Creatinine 
Ratio (mg/g)13 
  <30 
   30 – 300 
   >300 
 
 
90.4 (89.2-91.6) 
8.3 (7.4-9.2) 
1.3 (0.94-1.7) 
 
 
5.7 (4.6-6.8) 
7.6 (4.3-10.8) 
12.9 (6.7-19.2) 
 
 
94.3 (93.2-95.4) 
92.4 (89.2-95.7) 
87.1 (80.8-93.3) 
 
 
0.01 
HepB Core Ab14 
   Positive 
   Negative 
 
4.6 (3.6-5.5) 
95.4 (94.5-96.4) 
 
18.0 (11.6-24.4) 
5.3 (4.3-6.3) 
 
82.0 (75.6-88.4) 
94.7 (93.7-95.7) 
 
<0.01 
HepB Surface Ag15 
   Positive 
   Negative 
 
0.34 (0.20-0.48) 
99.7 (99.5-99.8) 
 
23.0 (8.2-37.7) 
5.8 (4.8-6.8) 
 
77.0 (62.3-91.8) 
94.2 (93.2-95.2) 
 
<0.01 
HepC Ab (confirmed)16 
   Positive 
   Negative 
 
1.7 (1.0-2.3) 
98.3 (97.7-99.0) 
 
5.1 (0.60-9.6) 
5.9 (4.9-6.9) 
 
94.9 (90.4-99.4) 
94.1 (93.1-95.1) 
 
0.71 
Self-reported 
Hypertension17 
   Yes 
   No 
 
31.5 (28.4-34.7) 
68.5 (65.3-71.6) 
 
7.3 (5.6-9.0) 
5.3 (4.3-6.3) 
 
92.7 (91.0-94.4) 
94.7 (93.7-95.7) 
 
<0.01 
Total Bilirubin 
(mg/dL)18 
   Normal 
   Not Normal 
 
 
98.7 (98.0-99.4) 
1.3 (0.59-2.0) 
 
 
5.9 (4.9-6.9) 
3.6 (0-8.7) 
 
 
94.1 (93.1-95.1) 
96.4 (91.3-100) 
 
 
0.45 
Total Cholesterol 
(mg/dL)19 
   <200 
   200-239 
   ≥240 
 
 
56.9 (55.0-58.8) 
30.1 (28.4-31.7) 
13.0 (11.4-14.7) 
 
 
5.8 (4.7-6.9) 
6.2 (4.6-7.8) 
5.6 (4.0-7.1) 
 
 
94.2 (93.1-95.3) 
93.8 (92.2-95.4) 
94.4 (92.9-96.0) 
 
 
0.74 
HDL Cholesterol 
(mg/dL)20 
   <40 
   40 – 59 
   ≥60 
 
 
17.4 (14.7-20.1) 
54.7 (51.9-57.6) 
27.9 (25.5-30.2) 
 
 
7.1 (5.2-9.0) 
5.8 (4.8-6.8) 
5.3 (3.5-7.0) 
 
 
92.9 (91.0-94.8) 
94.2 (93.2-95.2) 
94.7 (93.0-96.5) 
 
 
0.23 
Table 2 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-
tuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core 
antibody; HBsAg-hepatitis B surface antigen; Anti-HCV-hepatitis C antibody 
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1: Positive LTBI defined by positive QFT-GIT result. 
2: Negative LTBI defined by negative QFT-GIT result. 
3: All p-values obtained using Rao-Scott chi-square. 
4: BMI categories defined according to CDC guidelines[64]. 
5: Foreign born individuals include those who reported being born in one of the five United States territories. 
6: Positive TST defined as an induration >10mm[85]. 
7: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had diabetes) and according to American Diabetes Association guidelines; participants who self-reported 
diabetes were classified as having diabetes regardless of HbA1c. 
8: HbA1c categories determined according to American Diabetes Association guidelines[61]. 
9: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and 
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at 
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked 
at least 100 cigarettes in their lifetime defined as never having smoked[65, 85]. 
10: Determined by participant’s response to “Were you ever told that you had active tuberculosis or TB?” 
11: Determined by participant’s response to “Were you ever prescribed any medicine to treat active tuberculosis or 
TB?”; specific medicine type not asked. 
12: Ratio of family income to poverty guidelines; poverty guidelines as determined by the Department of Health and 
Human Services (HHS) used as poverty measure to calculate ratio of family income to poverty[85]. 
13: Categories for Albumin/Creatinine Ratio (ACR) defined according to National Kidney Foundation guidelines for 
albuminaria categories in chronic kidney disease (CKD)[67]. 
14: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[85]. 
15: HBsAg; only tested if participant had positive result for anti-HBc; positive/negative result determined by 
response to VITROS HBsAg assay; participants that tested negative for anti-HBc also coded as negative for 
HBsAg[85]. 
16: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with 
repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 
Strip[85]. 
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17: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had hypertension/high blood pressure)[85]. 
18: Categories for Total Bilirubin defined according to Medline Plus guidelines[84]. 
19: Categories for Total Cholesterol defined according to National Institutes of Health guidelines[69]. 
20: Categories for HDL Cholesterol defined according to Medline Plus guidelines[70]. 
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Table 3: Multivariable models for odds of latent tuberculosis infection by diabetes status in the civilian, 
non-institutionalized United States population aged 20 years and older, 2011-2012 
Models Crude Odds Ratio (95% CI) Adjusted Odds Ratio (95% CI)1 
Model 1: 
   No Diabetes2 
   Prediabetes 
   Diabetes 
 
1.00 
1.54 (1.24 – 1.91) 
2.70 (1.76 – 4.14) 
 
1.00  
1.15 (0.90 – 1.47) 
1.90 (1.15 – 3.14) 
Model 2: 
   No Diabetes3 
   Diabetes 
 
1.00 
2.38 (1.58 – 3.59) 
 
1.00 
1.80 (1.14 – 2.83) 
Model 3: 
   No Diabetes 
   Undiagnosed Diabetes4 
   Diagnosed Diabetes 
 
1.00 
3.06 (1.61 – 5.82) 
2.22 (1.46 – 3.38) 
 
1.00 
1.96 (1.05 – 3.68) 
1.75 (1.09 – 2.80) 
Model 4: HbA1c (%)5 
   <5.7% 
   5.7-6.4% 
   ≥6.5% 
 
1.00 
1.71 (1.33 – 2.19) 
2.50 (1.64 – 3.81) 
 
1.00 
1.30 (0.96 – 1.75) 
1.67 (1.04 – 2.69) 
Model 5: HbA1c (%) 
   <5.7 
   5.7-6.4 
   6.5-7.5 
   7.6-8.5 
   >8.5 
 
1.00 
1.71 (1.33 – 2.19) 
2.44 (1.48 – 4.01) 
3.12 (1.62 – 6.02) 
2.21 (1.08 – 4.51) 
 
1.00 
1.30 (0.96 – 1.75) 
1.66 (0.99 – 2.80) 
1.96 (1.06 – 3.63) 
1.50 (0.70 – 3.22) 
1: Models adjusted for age (categorized as 20-35 years, 35-65 years, and ≥65 years), sex (female, male), smoking 
status (current, former, never), history of active TB (yes, no), and foreign born status (yes, no). 
2: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who self-
reported diabetes were classified as having diabetes regardless of HbA1c. 
3: Individuals classified as having prediabetes or no diabetes for Model 1 were classified as not having diabetes for 
Model 2. 
4: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these 
previously undiagnosed participants have no information for duration of diabetes[85]. 
5: Glycated hemoglobin (HbA1c) categories determined according to American Diabetes Association 
guidelines[61]. 
Bold indicates that the adjusted odds ratio (aOR) is statistically significant 
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Table 4: Weighted prevalence of latent tuberculosis (LTBI) infection among only those with diabetes1 in 
the civilian, non-institutionalized United States population, adults 20 years and older, 2011-2012 
Participant 
Characteristics 
Totals for 
Population 
N=793 
%  (95% CI) 
 
LTBI Positive2 
% (95% CI) 
11.6 
(7.9-15.3) 
LTBI Negative3 
% (95% CI) 
88.4 
(84.7-92.1) 
p-value4 
Age (years) 
   20 – 34 
   35 – 64 
   ≥65 
 
4.8 (3.2-6.4) 
59.9 (55.4-64.6) 
35.3 (30.8-39.8) 
 
9.2 (0-21.4) 
10.9 (5.5-16.2) 
13.1 (9.0-17.3) 
 
90.8 (78.6-100) 
89.1 (83.8-94.5) 
86.9 (82.7-91.0) 
 
0.71 
Sex 
   Female 
   Male 
 
50.7 (45.6-55.8) 
49.3 (44.2-54.4) 
 
11.1 (7.1-15.0) 
12.1 (7.6-16.6) 
 
88.9 (85.0-92.9) 
87.9 (83.4-92.4) 
 
0.59 
Race/Ethnicity 
   Hispanic 
   NH White 
   NH Black 
   NH Asian 
 
17.3 (9.5-25.2) 
58.4 (46.3-70.5) 
18.3 (10.2-26.3) 
6.0 (3.4-8.7) 
 
24.3 (12.4-36.2) 
6.9 (3.2-10.6) 
11.7 (7.5-15.9) 
27.5 (19.0-35.9) 
 
75.7 (63.8-87.6) 
93.1 (89.4-96.8) 
88.3 (84.1-92.5) 
72.5 (64.1-81.0) 
 
<0.01 
Foreign Born5 
   No 
   Yes 
 
79.3 (73.3-85.3) 
20.7 (14.7-26.7) 
 
6.8 (4.4-9.1) 
30.2 (18.8-41.6) 
 
93.2 (90.9-95.6) 
69.8 (58.4-81.2) 
 
<0.01 
Smoking Status6 
   Current 
   Former 
   Never 
 
18.0 (14.7-21.3) 
32.2 (27.1-37.3) 
49.9 (43.7-56.0) 
 
12.5 (7.1-17.8) 
14.5 (7.8-21.3) 
9.4 (5.1-13.8) 
 
87.5 (82.2-92.9) 
85.5 (78.7-92.2) 
90.6 (86.2-95.0) 
 
0.21 
Diabetes Duration (years)7 
   Undiagnosed8 
   <1 
   1-3 
   4-10 
   ≥10 
 
19.9 (15.3-24.4) 
4.8 (2.3-7.2) 
16.5 (11.2-21.7) 
26.0 (22.7-29.4) 
32.9 (26.7-39.0) 
 
14.4 (6.7-22.2) 
3.6 (0-8.0) 
9.3 (3.1-15.6) 
11.1 (6.0-16.3) 
12.5 (7.3-17.7) 
 
85.6 (77.8-93.3) 
96.4 (92.0-100) 
90.7 (84.4-96.9) 
88.9 (83.7-94.0) 
87.5 (82.3-92.7) 
 
0.32 
Diabetes Diagnosis Status 
   Undiagnosed 
   Diagnosed 
 
19.9 (15.3-24.4) 
80.1 (75.6-84.7) 
 
14.4 (6.7-22.2) 
10.9 (7.4-14.4) 
 
85.6 (77.8-93.3) 
89.1 (85.6-92.6) 
 
0.24 
Taking insulin 
   Yes 
   No 
 
23.5 (18.4-28.5) 
76.5 (71.5-81.6) 
 
7.3 (3.1-11.4) 
12.9 (8.5-17.3) 
 
92.7 (88.6-96.9) 
87.1 (82.7-91.5) 
 
0.03 
How long taking insulin 
(months)9 
   1-12 
   13-24 
   25-36 
   >36 
 
 
20.9 (13.9-27.9) 
11.0 (4.7-17.4) 
6.3 (0-13.7) 
61.8 (49.1-74.4) 
 
 
7.2 (0-15.5) 
11.0 (0-29.4) 
23.0 (3.1-43.0) 
4.7 (0.99-8.4) 
 
 
92.8 (84.5-100) 
89.0 (70.6-100) 
77.0 (57.0-96.9) 
95.3 (91.6-99.0) 
 
 
0.09 
Oral Agents10 
   Yes 
   No 
 
60.4 (55.1-65.6) 
39.6 (34.4-44.9) 
 
12.0 (7.5-16.4) 
11.0 (6.8-15.2) 
 
88.0 (83.6-92.5) 
89.0 (84.8-93.2) 
 
0.65 
HbA1c (%)11     
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   <5.7 
   5.7-6.4 
   6.5-7.5 
   7.6-8.5 
   >8.5 
5.4 (3.1-7.6) 
23.4 (17.1-29.8) 
34.8 (28.8-40.7) 
14.5 (10.2-18.8) 
21.9 (17.7-26.1) 
9.1 (2.3-16.0) 
14.1 (5.9-22.4) 
10.7 (6.2-15.2) 
13.3 (5.3-21.3) 
9.8 (3.9-15.7) 
90.9 (84.0-97.7) 
85.9 (77.6-94.1) 
89.3 (84.8-93.8) 
86.7 (78.7-94.7) 
90.2 (84.3-96.1) 
0.71 
HepB Core Ab12 
   Positive 
   Negative 
 
7.8 (5.0-10.7) 
92.2 (89.3-95.0) 
 
20.8 (8.9-32.7) 
11.0 (7.2-14.9) 
 
79.2 (67.3-91.1) 
89.0 (85.1-92.8) 
 
0.04 
HepC Ab (confirmed)13 
   Positive 
   Negative 
 
2.9 (0.80-5.1) 
97.1 (94.9-99.2) 
 
3.8 (0-10.4) 
12.0 (8.3-15.8) 
 
96.2 (89.6-100) 
88.0 (84.2-91.7) 
 
0.06 
Self-reported 
Hypertension14 
   Yes 
   No 
 
64.6 (60.8-68.3) 
35.4 (31.7-39.2) 
 
10.6 (6.7-14.5) 
13.4 (7.4-19.4) 
 
89.4 (85.5-93.3) 
86.6 (80.6-92.6) 
 
0.31 
Total Cholesterol (mg/dL)15 
   <200 
   200-239 
   ≥240 
 
64.6 (60.0-69.2) 
24.1 (20.2-28.0) 
11.3 (7.4-15.1) 
 
10.4 (6.8-13.9) 
14.9 (6.9-22.9) 
13.4 (1.8-24.9) 
 
89.6 (86.1-93.2) 
85.1 (77.1-93.1) 
86.6 (75.1-98.2) 
 
0.43 
HDL Cholesterol (mg/dL)16 
   <40 
   40-59 
   ≥60 
 
29.6 (21.9-37.2) 
57.7 (49.7-65.7) 
12.7 (9.1-16.4) 
 
11.9 (6.2-17.6) 
11.1 (6.7-15.5) 
14.5 (4.3-24.7) 
 
88.1 (82.4-93.8) 
88.9 (84.5-93.3) 
85.5 (75.3-95.7) 
 
0.75 
Table 4 Abbreviations: BMI-body mass index; LTBI-latent TB infection; HbA1c-glycated hemoglobin; TST-
tuberculin skin test; QFT-GIT-QuantiFERON®-TB Gold In-Tube; NH-Non-Hispanic; Anti-HBc-hepatitis B core 
antibody; Anti-HCV-hepatitis C antibody 
1: Diabetes determined by self-report (answered “yes” to having been told by a doctor or health professional that 
he/she had diabetes) and according to American Diabetes Association guidelines as having an HbA1c (glycated 
hemoglobin) level ≥6.5%[61]; participants who self-reported diabetes were classified as having diabetes regardless 
of HbA1c. 
2: Positive LTBI defined by positive QFT-GIT result. 
3: Negative LTBI defined by negative QFT-GIT result. 
4: All p-values obtained using Rao-Scott chi-square. 
5: Foreign born individuals include those who reported being born in one of the five United States territories. 
6: Current smokers defined as those who self-reported having smoked at least 100 cigarettes in their lifetime and 
currently smoking every day or some days; former smokers defined as those who self-reported having smoked at 
least 10 cigarettes in their lifetime but are not currently smoking at all; participants who reported not having smoked 
at least 100 cigarettes in their lifetime defined as never having smoked[65, 85]. 
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7: Refers to how long participant has known they have diabetes; this was calculated using the age of the participant 
and his/her response to the survey question regarding how old he/she was when a doctor or other health professional 
first told him/her that he/she had diabetes or sugar diabetes[85]. 
8: Participants with diabetes who were unaware they had diabetes were classified as previously undiagnosed; these 
previously undiagnosed participants have no information for duration of diabetes[85]. 
9: Among participants who answered “yes” to taking insulin. 
10: Determined by response to survey question “Are you now taking diabetic pills to lower your blood sugar?”; 
specific medications not determined[85]. 
11: HbA1c categories determined according to American Diabetes Association guidelines[61]. 
12: Anti-HBc; positive/negative result determined by response to VITROS Anti-HBc assay[85]. 
13: Anti-HCV; participants first screened for anti-HCV using VITROS Anti-HCV assay; participants with 
repeatedly positive reactions to anti-HCV assay are then confirmed positive using the Chiron RIBA HCV 3.0 
Strip[85]. 
14: Hypertension determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had hypertension/high blood pressure)[85]. 
15: Categories for Total Cholesterol defined according to National Institute of Health guidelines[69]. 
16: Categories for HDL Cholesterol defined according to Medline Plus guidelines[70]. 
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Supplemental Table 1: Multivariable models for odds of latent tuberculosis infection associated with 
diabetes status in the civilian, non-institutionalized United States population aged 20 years and older, 
2011-2012: 
Models Adjusted Odds Ratio 
(95% CI) 
Covariates1 
Model 1 
   No Diabetes2 
   Prediabetes 
   Diabetes 
 
1.00 
0.95 (0.75 – 1.21) 
1.49 (0.83 – 2.68) 
age, sex, education, previous history of active TB, 
ethnicity, income to poverty ratio, ACR, HepB surface 
antigen, HepB core antibody, smoking status, foreign 
born status, and hypertension 
Model 2 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
1.00 
1.21 (0.90 – 1.62) 
2.04 (1.17 – 3.57) 
age, sex, ACR, HepB surface antigen, and HepB core 
antibody 
 
Model 3 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
1.00 
1.06 (0.81 – 1.35) 
1.49 (0.84 – 2.64) 
age, sex, education, ethnicity, and income to poverty 
ratio 
Model 4 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
1.00 
1.05 (0.82 – 1.35) 
1.55 (0.91 – 2.65) 
age, sex, ethnicity, country of birth, income to poverty 
ratio, smoking status, and education 
Model 5 
   No Diabetes  
   Prediabetes 
   Diabetes 
 
1.00 
1.25 (0.93 – 1.68) 
2.20 (1.22 – 3.96) 
age, sex, BMI, ACR, HepB surface antigen, HepB 
core antibody and hypertension 
Model 6 
   No Diabetes  
   Prediabetes 
   Diabetes 
 
1.00 
1.07 (0.83 – 1.37) 
1.67 (1.01 – 2.74) 
age, sex, smoking status, ethnicity, and country of 
birth 
 
Model 7 
   No Diabetes  
   Prediabetes 
   Diabetes 
 
1.00 
1.09 (0.79 – 1.41) 
1.61 (0.86 – 2.99) 
age, sex, BMI, hypertension, ethnicity, and income to 
poverty ratio 
 
Model 8 
   No Diabetes  
   Prediabetes 
   Diabetes 
 
1.00 
1.17 (0.92 – 1.49) 
1.93 (1.17 – 3.21) 
age, sex, country of birth, previous history of active 
TB, and smoking status 
Model 9 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
1.00 
1.22 (0.93 – 1.60) 
1.86 (1.00 – 3.46) 
age, sex, BMI, education, and income to poverty ratio 
 
Model 10 
   No Diabetes 
   Prediabetes 
   Diabetes 
 
1.00 
1.12 (0.84 – 1.49) 
1.76 (1.02 – 3.03) 
age, sex, ethnicity, BMI, and country of birth 
Supplemental Table 1 Abbreviations: TB-tuberculosis; ACR-albumin-creatinine ratio  
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1: Covariates controlled for in multivariable logistic model. 
2: Diabetes status determined by self-report (answered “yes” to having been told by a doctor or health professional 
that he/she had diabetes) and according to American Diabetes Association guidelines[61]; participants who self-
reported diabetes were classified as having diabetes regardless of HbA1c. 
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Figure 1: Flow chart showing process of selection for NHANES 2011-2012 participants eligible for study, 
including the categorization of eligible participants by diabetes status; raw numbers and percentages not 
weighted for NHANES sampling methodology. 
 
 
 
